The life sciences industry remains a cornerstone of the UK’s economy and healthcare system, playing a pivotal role in driving economic growth and improving health outcomes through innovative treatments. Since 2006, Cpl Life Sciences has delivered staffing solutions and market insights to thousands of companies globally. In this 2025 Year in Review, we analyse a year defined by strategic adjustment and capital discipline as the sector navigated a more selective investment landscape.
2025 was a year of consolidation for hiring in Life Sciences. Following a period of stabilisation, total scientific vacancies across the UK declined by 7% to 6,971 job postings. This contraction was largely driven by boards prioritising cash efficiency and delaying clinical programs rather than a decline in scientific fundamentals. Geographically, London maintained its dominance despite a 5.3% fall in activity, while South East England emerged as a resilient hub with 8.5% growth. Notably, the North East saw a dramatic 75.9% surge in vacancies, fueled by new regional investment and research funding in Newcastle.
From a sectorial perspective, Pharmaceuticals remained the largest recruiter, accounting for 3,606 vacancies, despite a 7.3% decline. Biotech and CRO sectors followed similar patterns of moderate contraction. However, the year started with significant momentum; Q1 2025 was the strongest quarter for all sectors, with hiring peaking in March.
Our data regarding skills in demand reveals a shifting focus toward strategic oversight and pipeline value. While Sales remained the most in-demand profession, Executive Management roles saw an unprecedented surge of 272.8% as firms emphasized restructuring and capital discipline. Additionally, R&D vacancies rose by 12.3%, reflecting a renewed prioritisation of roles linked to milestone delivery.
Among the top firms, GSK continued to lead as the single largest recruiter by volume. We saw impressive growth from Roche (+58.1%) and a sharp recovery for Lonza (+52.9%), while AstraZeneca faced a second year of contraction amid investment delays.
The life sciences sector is entering a pivotal phase where innovation must align seamlessly with regulatory expectations. As artificial intelligence becomes embedded across quality, manufacturing, and regulatory operations, the industry is shifting from early experimentation to a stronger emphasis on reliability, validation, and operational integrity.
We maintain a highly positive outlook for 2026. Venture capital raised in 2025 was nearly double that of 2024, signaling that as this funding feeds into execution, we can expect a return to growth. Life Sciences will always be about people working together for a healthier future, and Cpl Life Sciences is here to support you with the human touch necessary to navigate this evolving landscape.
For the full report Click Here
Drew Jones - Operations Director